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Review Al'licle
Haemophilia
E. P. GETAZ, W. G. STAPLES, A.LURlE
SUMMARY
The clinical and haematological features of haemophilia
are reviewed and the historical aspects, pathogenesis and
genetics are discussed. The problems associated with
management, such as factor replacement, home therapy,
physiotherapy, surgical intervention and the presence of
inhibitors, are fully described. Finally, mention is made
of the psychological problems of haemophiliacs and of the
help given by the South African Haemophilia Foundation.
S. Air. med. J., 52, 595 (1977).
Haemophilia is a congenital bleeding disorder which has
been known for many hundreds of years. It afflicts pre-
dominantly males and is usually carried by asymptomatic
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females. The disorder encompasses classic haemophilia
(haemophilia A) and Christmas disease (haemophilia B)
and is caused by a deficiency of functional factor VIII
or factor IX.
The currently accepted theory of blood coagulation
shows that both factor VUl and factor IX are early re·
actants in the coagulation sequence (Fig. I). The deficiency
in the plasma protein may be either quantitative or quali·
tative. Bio-assay of factor Vn! coagulant activity (VIIIc)
in (he plasma of patients reveals a quantitative deficiency.
Immunological testing, however, shows the presence of
normal quantities of a substance, antigenically similar to
factor VIlI, in the plasma of patients with haemophilia
A (VUIAgn).' A similar situation exists in Christmas
disease, where there is deficient factor IX coagulant
activity, yet normal amounts of a factor IX-related pro-
tein when tested immunologicaJly. In haemophilia B
Leyden there is an absence of factor IX activity on
immunological testing' and it is remarkable that the
levels of coagulant factor IX tend to rise with age in this
rare genetic variant."
DEFINITIONS
A unit of factor VIII or IX functional activity is defined
as that activity present in 1 millilitre of normal blood.
This ranges from 50% to 150o~ with a mean of ±
100o~. A unit of cryoprecipitate is the amount of cold-
precipitated factor VIII obtained from 500 ml of whole
blood from a normal donor. A unit of fresh frozen plasma
(FFP) is that amount obtained from 500 ml of whole
blood from a normal donor.
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Fig. 1. Simplified scheme illustrating the importance of factors VlII and IX in the coagulation pathway.
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THE IDSTORY OF HAEMOPHILIA
This has recently been extensively reviewed by Ingram:
The earliest references to haemophilia are in the Talmud.
The rabbi Simon ben Gamaliel forbade the circumcision
of a boy because the sons of his mother's three elder
sisters had died after circumcision. Maimonides, a 12th
century Jewish physician, applied the rabbinic ruling to
the sons of a woman who was twice married.
Otto,' in 1803, gave a clear account of the disease and
noted that the illness occurred only in males and appeared
to be transferred by unaffected females. A very full review
of the subject was given by Nassec in 1820. The term
'haemophilia' appears to have been used first by Hopff in
1828 and again by Schonlein in 1839.'
In the Royal Houses of Europe, haemophilia occurred
in Leopold, the eighth child of Queen Victoria. It is
assumed that the mutation occurred in Queen Victoria's
father, Edward, Duke of Kent, or perhaps in herself,
since there was no previous indication of the disorder in
the family. The best known royal haemophiliac was un-
doubtedly the Russian Prince Alexis, the son of Tsar
Nicholas II and Tsarina Alexandra.
Of interest, too, is that haemophilia occurs in horses and
in dogs. This indicates that the mutation rate must be
relatively high, because haemophilic animals would pro-
bably not survive in the wild state.
INCIDENCE
The incidence of this relatively uncommon disease in its
severe form is about 1 in 25000 live births, but may be
very much higher in certain communities such as Sweden,
where the incidence has been recorded as 1 in 7 000.'"
Haemophilia A is 5 - 8 times more common than Christ-
mas disease. Lurie and Jenkins'° undertook a comprehen-
sive survey of the incidence of haemophilia in South
Africa, assimilating data from the Cape, Transvaal and
Natal and found that the incidence of haemophilia inWhit~ South Africans does not differ significantly from
generally accepted figures. There was a suggestion that the
incidence of haemophilia may be somewhat lower in the
Black population, but in view of the geographical distri-
bution, a spuriously low incidence may have been ob-
tained. They felt that in the Coloured and Black popu-
lation groups the lower number of less severely affected
patients may have been due to under-reporting.
INHERITANCE
Both haemophilia A and haemophilia B are transmitted
as sex-linked recessive conditions. When a haemophiliac
marries a normal female, his daughters will be obligate
carriers of the affliction and his sons will be unaffected.
A carrier female who marries a normal male will produce
sons with a 50% chance of being affected, and daughters
with the same chance of being carriers of the gene (Fig. 2).
Only if an affected male marries a carrier female may the
daughter of such a union be a haemophiliac.
There is often a family history of 'bleeders' among male
relatives, but some 25 - 30% of patients give no family
history of the disease. This may be due to the relatively
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Fig. 2. Inheritance of haemophilia.
high rate of mutation of the gene or to the disorder being
passed down several generations of females with no
affected males in the family. The occurrence in a male in
a later generation would appear to be due to a new muta-
tion. True haemophilia may occur in females if the mother
is a carrier of the gene and if the father is affected, but
this is obviously extremely rare."·12 In addition, haemo-
philia A has been reported in XX/X013 and XX/XXX
mosaicism" and haemophilia B in Turner's syndrome
(XO),15 the haemophilia gene residing on the X chromo-
some present. In other cases of severe female haemophilia
with no evidence of chromosomal deviations, a mutation
in the second X chromosome has been assumed to explain
the occurrence of a homozygous female bleeder. lB,ll
Recently 3 generations of women with apparent dominant
inheritance of haemophilia A have been described." Tn
spite of low factor VIIIc levels in the range of 2 - 5°;,
their clinical course has been extremely mild.
Carriers of the gene may themselves bleed more than
normal, and if the factor VTIIc is low enough (less than
5%) these individuals may be severely affected and may
experience spontaneous haemorrhages into muscles and
joints in the same way as severely affected haemophiliacs."
Although carriers with levels over 30% are generally un-
affected clinically, we have seen a patient who, in spite of
a level of 34%, has had severe bleeding episodes.
The factor VITIc level of a carrier is often below or at
the lower limit of the normal range. In view of the over-
lap, the carrier state may be detected in approximately
25% of haemophilia carriers by functional factor VIII
assays only: Gomperts et al.," using the ratio of functional
factor VIII levels to factor VIII-related antigen (VIIIc/
VIIIAgn), have confirmed earlier reports"21,,, that below a
ratio of 0,65 the carrier status could be predicted within
the 95 % confidence limits.
The expression of the gene within a single family tends
to run true, in that severely affected haemophiliacs usually
have severely affected relatives and those with a mild
affliction produce mildly afflicted offspring.
THE CLINICAL PICTURE
The clinical picture is usually directly related to the level
of functional factor VIII in the patient's plasma. Patients
are classified as being severely, moderately severely, and
mildly affected.
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Severely Affected
Less than 1% of haemophiliacs are severely affected.
These patients suffer spontaneous bleeding into joints and
muscles, often with crippling deformity.
Moderately Severely Affected
Between 1% and 5?o of haemophiliacs are moderately
severely affected. These patients have less frequent
haemarthroses and muscle haemorrhages than the first
group. The low level of factor VIII affords some pro-
tection, but deformities are still frequent.
Mildly Affected
In 5 - 30% of haemophiliacs the disease is mild. Spon-
taneous bleeding and haemarthroses are uncommon in
these patients, but they suffer excessive haemorrhage after
trauma, tooth extractions and surgery. These patients are
often unaware of their haemorrhagic tendency until they
are subjected to major trauma or surgery.
Between the upper ranges of the mildly affected group
and the lower limit of normal is a group of patients in
whom the diagnosis is often missed. and in whom the
only symptom is a tendency to excessive haemorrhage
after major trauma.
Haemorrhages may commence early in life, for example,
at the time of circumcision. If the child is not circumcised,
easy bruising may be noted early, or the diagnosis may be
delayed until about the age of 7 - months. when the
child becomes more mobile and more exposed to trauma.
Joint and Muscle Bleeding
The most common haemorrhagic manifestation of the
severely affected haemophiliac is bleeding into joint cavi-
ties, especially the knees, elbows and ankles. These
haemorrhages typically result from such trivial trauma
that they are not noticed, or may arise spontaneously. The
source of the bleeding is probably the synovial membrane.
The blood fills and distorts the joint cavity and causes
pain and muscular spasm, which increases the pressure
on the joint. Repeated haemorrhages into the joints lead
to thickening and increased vascularity of the synovium
and damage to articular cartilage. Resorption of blood
from the joint is often incomplete and the result is a
chronically damaged and painful joint with thickened
synovium. Decreased function resulting from the de-
formity often causes muscle wasting around the joint.
The protective influence of' the musculature around the
joint is defective and recurrent trauma to the joint occurs
easily. This is applicable particularly to the knee joint. A
vicious cycle is set up and often leads to severe deformity
after repeated bleeds. The final stage is one of ankylosis
of the joint. The larger joints are more commonly affected
than the smaller joints. and hinge joints are affected more
often than ball-and-socket joints.
The clinical picture of acute haemarthrosis is that of a
distended, warm. exquisitely painful joint with surrounding
muscle spasm and loss of movement. The joint i usually
8
held in a position of flexion. which decreases tension on
the joint capsule.
Muscle Haematomas
Haemorrhages into muscle occur either spontaneously or
after trauma. A large haemorrhage under tension within
a fascial compartment may occasionally lead to occlusion
of the arterial flow. producing a mu c1e infarct, necro i .
and a true Volkmann's ischaemic contracture. Damage to
associated nerves may add to the peripheral deformity.
The flexor group of forearm muscles is commonly affected
in this manner." A less well-recognized form of muscle
necrosis may also occur. Deep haemorrhage may be pain-
less and insidious. and may obstruct capillary circulation
rather than main arterial inflow. This leads to patchy
muscle fibre necrosis, rou,ld cell infiltration and irregular
fibrous replacement of dead tissue, with ultimate shorten-
ing of the affected muscles. Associated joints which are
otherwise normal may be pulled into a position of fixed
deformity. The calf is particularly usceptible to this type
of insult and fixed equinus deformity of the foot is com-
monly seen in haemophiliacs.'" One of the mu cle groups
most affected by bleeding i the iliopsoas; with the pro-
duction of pain. leucocytosis and fever the differential
diagnosis from appendicitis may be difficult.
Intra-abdominal Bleeding
Intra-abdominal bleeding may be retroperitoneal, intra-
peritoneal or within an organ. Retroperitoneal bleeding is
not uncommon and, with intraperitoneal bleeding. may
mimic surgical conditions. Haematemesis, melaena and
haematuria are not uncommon, and may be severe and
even life-threatening. The haemorrhage may originate
anywhere in the gastro-intestinal or renal sy tems.
Intracranial Haemorrhage
Intracranial haemorrhage is extremely dangerous. tend
to occur in younger patients in relation to trauma. and
may be intracranial. subdural, or subarachnoid. It is the
commonest cau e of death in haemophiliacs. and any
head trauma in haemophilic patients. no matter how
trivial, requires close attention.
Pseudotumours
One of the most severe. but fortunately rare. problems
in haemophilia is the development of haemophilic pseudu-
tumours or cysts as a late complication of bleeding.
After a haemorrhage into a fascial space or subperios-
teally. the haematoma may grow as a result of breakdown
of blood. with increased osmotic pressure drawing fluid
into the cyst. or from repeated bleeding, or from both.
These cysts are most common in the vicinity of the hip
but may occur in any site. Their continued growth leads
to local pressure effects. often with bony destruction. They
may destroy joint and mu c1es. may perforate the abdo-
mina! wall, or may lead to perforation of hollow muscular
organs. with fistula formation. They are difficult to treat
and tend to recur after incomplete removal. arly treat-
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ment of deep bleeding episodes has decreased the fre-
quency of this complication.
MANAGEMENT OF THE ACUTE
HAEMORRHAGE
This may be considered under two separate headings:
(i) specific factor replacement therapy, and (ii) supportive
treatment during the acute phase.
Specific Factor Replacement Therapy
This requires replacement of the factor lacking in the
coagulation pathway by fresh blood, fresh frozen plasma,
cryoprecipitate or factor concentrate. The earliest record
of transfusion in the therapy of haemophilia was probably
that of Lane,'" who performed a direct transfusion of
340 ml of blood from a woman to an ll-year-old boy
who had bled for 6 days after an operation for a squint.
After the transfusion, the bleeding stopped and the boy
recovered.
Fresh blood contains factor VIII but is unsuitable for
therapy in haemophilia A because of the volume required
to elevate the patient's factor VIII level and the time taken
to infuse whole blood.
Fresh frozen plasma (FFP) is effective in managing
bleeding of a minor degree. If fresh plasma is frozen and
thawed, 20 - 30% of the original factor VIII content will
be lost."" Factor VIII has a rapid turnover in vivo with a
half-life of ± 12 hours. In the presence of bleeding and in
fever and infections, the half-life of factor VIII may be
shortened even further to 8 - ID hours.""" In the presence
of severe haemophilia and/or severe haemorrhage, use
should be made of cryoprecipitate or a concentrate of
factor VIII, to avoid the danger of overhydration.
Cryoprecipitate. When FFP is thawed at 4cC a
precipitate rich in factor VIII remains.'" This precipitate
may be dissolved at 37°C in a small volume (30 - 50 mn
and has been used extensively as a concentrated form of
factor VIII for factor VIII replacement therapy. One unit
of cryoprecipitate is that amount harvested from 500 ml
of whole blood. The quantity of factor VIII in 1 unit of
cryoprecipitate varies widely, but averages 80 - 100 units.
The decision whether to use FFP or cryoprecipitate
depends on the availability of either product in a particu-
lar area. It does not matter which is utilized, provided that
an adequate dose of factor VIII is infused to stop the
haemorrhage. The choice then becomes one of availability
and economics, both in finance and in donor material. FFP
has the advantage that it is relatively inexpensive and
widely available and has a more reliable activity. Its dis-
advantage is the volume infused. Cryoprecipitate has the
advantage of small volume and therefore of ease and
rapidity of infusion, but has the disadvantage of variable
factor VIII activity. As a result, more donor material is
utilized during its production and cryoprecipitate is there-
fore more expensive in terms of money and donors. FFP
is used mainly in the Transvaal and cryoprecipitate in the
Cape, OFS and atal.
Concentrated preparations. Several types of concentrates
are available in South Africa: (i) those produced by
several blood transfusion services in strengths of 125 and
250 units of dried factor VIII and reconstituted with 50 ml
of saline; (ii) commercial concentrates produced in the
USA, such as Hemofil, which contain 700 - 800 units of
factor VIII in 30 ml and which are derived from human
factor VIII sources; and (iii) concentrates of bovine and
porcine factor VIII.
Supportive Therapy
Supportive therapy is important in the treatment of
acute haemorrhages. The symptom which requires most
attention is pain. The presence of blood in the joint causes
increased intra-articular pressure with capsular distension
and resultant pain which may be so severe as to necessitate
pethidine or morphine. Intramuscular injection should be
avoided until factor VIII replacement therapy has been
commenced, because extensive bruising may occur at the
injection site. Pentazocine may also prove useful if the
pain is not too severe. For mild analgesia either para-
cetamol, propoxyphene, or combinations of the two, may
be used. These agents have very little effect on platelet
function, whereas the adverse effects of aspirin on platelet
function and gastric mucosae preclude the use of aspirin-
containing compounds.
During an acute episode of joint bleeding, the affected
joint should be immobilized in the position of maximum
comfort, preferably by means of a well-fitting back-slab
or Robert-Jones bandage, which is retained until pain has
disappeared completely, usually after 24 - 48 hours.
Thereafter the back-slab should be applied at night for a
further week. During this time the physiotherapist should
instruct the patient to perform static quadriceps exercises,
followed by more extensive active exercises such as
straight leg raising when adequate muscle tone has been
regained. This is followed by active exercises against re-
sistance, and partial weight-bearing before a return to full
weight-bearing. A swimming pool for water-support
exercises is very useful. It usually takes 5 - 7 days before
partial or full weight-bearing is allowed.
In patients confined to bed after a major haemorrhage,
routine bed exercises help to prevent haemorrhages into
other joints. Before regular physiotherapy was started in
these patients, Cole and Jones'" frequently noted secondary
haemarthroses, particularly in the elbows, shoulders and
knees. The best time for physiotherapy is immediately
after replacement therapy has been given.
In those patients with chronic arthropathy, considerable
improvement in function may be obtained by graduated
exercise to strengthen the muscles surrounding the joint.
This should provide some protection against further
bleeding, as well as improve the range of joint function.
Useful supportive drugs are epsilon-aminocaproic acid
(Epsikapron) and tranexamic acid (Cyklokapron). These
fibrinolytic inhibitors are particularly useful after tooth
extraction but may also be used to stabilize the clot in
patients with severe bleeding who require high factor
VIII replacement. These agents are contraindicated in
haematuria because of possible formation of clots resistant
to lysis within the ureters, and consequent obstruction with
retrograde hydronephrosis.
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Aspiration of joints is seldom required, but may be of u e
in patients with very tense, painful, acute haemarthroses.
Aspiration should be performed only by a competent
operator, in a sterile theatre with full surgical technique
and under adequate cover with factor VIII.
HOME THERAPY
The advent of home infusions has altered the therapy of
haemophilia considerably. Home therapy, particularly
with lyophilized factor VIII, is now available to all who
have had the necessary instruction and who have adequate
peripherai veins and proper storage facilities. The pre-
parations most suitable at present are dried FFP,
dried factor VIII concentrate (cryoprecipitate or
intermediate potency agents) or Hemofil (Hyland Labora-
tories). Patients are trained to set up their own drips and
when they have acquired the skills. they are supplied
with dried factor VIII and the paraphernalia for intra-
venous infusions. A record should be kept of all haemor-
rhages and the amount of factor VIII used. Parents are
trained to set up infusions for young patients. The family
practitioner can also be of assistance to these patients.
The major advantage of home infusions is that there is
minimal delay between the commencement of the haemor-
rhage and the institution of treatment. This in turn re-
duces pain, deformity, crippling and absence from work.
A theoretical disadvantage is that the amount and cost
of treatment may be increased. It has been found,'" how-
ever, that home infusion leads to a relatively minor in-
crease in the amount of factor VIII used and the in-
creased risk of exposure to hepatitis virus is therefore
only marginal. The practical advantages of home therapy
far outweigh the disadvantages. Many patients have stated
that bleeding in a joint is more effectively treated at
home than by an inexperienced casualty officer, often
after many hours of delay. In addition, it should be re-
membered patients are often aware of early haemorrhage
long before there are physical signs of effusion.
Physiotherapy
The patient who treats himself haematologically can
usually also give Ilimself physiotherapy. However, this is
not always diligently carried out by patients on home
infusion programmes, and is one of the disadvantages
of home infusions.'" Active exercise is essential and the
sport most suited to the haemophiliac is swimming. Other
sports may be played, but contact sports should be
avoided.
SURGICAL INTERFERENCE
With adequate replacement therapy, there is no operation
that cannot be safely undertaken in a haemophiliac. For
surgery the most potent dried concentrates are necessary
and treatment needs to be continued until healing is com-
plete. The surgery most often undertaken in the haemo-
philic patient is orthopaedic correction of deformity,
usually of the knee or hip. Utilizing the concentrates
available in South Africa, we have performed synovec-
tomies, arthrodeses and total hip replacements.
On two occasions we have seen postoperative haemo-
lytic anaemia due to naturally occurring iso-antibodies
after the administration of large amounts of factor Vlll.
This has previou ly been documented, and a 50% fall in
haemoglobin levels over 6 - 9 days may occur in these
patients."-" It is recommended that for inten ive therapy
of patients of groups A, B, and AB only type- pecific
cryoprecipitate be u ed, if available, and that the use
of any other concentrates be restricted to a minimum by
titrating dosage to AHF levels." For symptomatic patients,
washed group 0 erythrocytes of appropriate Rh specificity
should be transfused.
Polytransfused patient are at risk of developing erum
hepatitis, and this risk increases proportionately to the
number of donors. Commercial factor VIII concentrates
are prepared from pool of 2000- 6000 litres of plasma
obtained by plasmapheresis from paid donors.''' Biggs,"
in a study of 37 haemophilia centres in the period 1969-
1971, found the incidence of hepatitis to be about 1,8 %.
More recently an outbreak of hepatitis a sociated with
factor VIII concentrate was reported from Bournemouth."
Fifty per cent of patients who received commercial con-
centrate developed hepatitis (4 hepatitis B, 7 hepatiti non-
B, 2 both types of hepatitis). The Australia antigen statu of
the patients hould be determined at least annually by
radio-immunoassay, but all blood, especially of severely
affected patients, should be considered potentially in-
fectious.
REPLACEME T REQUIREME TS
The patient's requirements are related to hi ba eline
factor level, the nature of the bleeding, the type and
potency of material used and it volume relative to the
patient's plasma volume. It should be remembered that
patients vary in their response to cryoprecipitate or dried
factor VIII preparations.
The patient should not be overloaded with fluid or
with plasma proteins. In patients receiving large amounts
of cryoprecipitate we have ob erved plasma protein con-
centrations of 10- 12 g/IOO ml, with the consequent effects
of increased osmotic pressure. This might have been
obviated by the use of dried factor VIII in situation re-
quiring prolonged and high-do e replacement therapy.
Minor bleeding requires that the factor VIII level be
raised to 10 - 20% for 1 - 5 day; whereas major joint
bleeding requires a level of 10 - 30% for 3 - 5 day. evere
haemorrhagic conditions such as head injurie, gastro-
intestinal haemorrhage or retroperitoneal haematoma, re-
quire elevation of factor VIII level to 30 - 50% for 7 - 14
days. Major surgical operations require a level of 50 - 70%
at operation and 20 - 40% for 14 days, especially in opera-
tions such as total hip replacement with muscle cutting,
raw bone surfaces and stripping of mu cle from bone.
Tooth extractions require elevation of factor VIII level to
20 - 40% at the time of operation, and then an anti-
fibrinolytic agent such as epsilon-aminocaproic acid or
tranexamic acid for 7 - 10 days. A u eful formula for the
determination of replacement therapy is:
dose of Wt (kg) x desired factor VIll rise (%)
factor VllI =
1,5
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As factor VIII has a half-life of approximately 12
hours, therapy may need to be given every 12 hours.
The principles of therapy in patients with factor IX
deficiency are essentially the same. However, the response
to infusion of factor IX is poorer than to that of factor
VIII and therefore more factor IX may be required. This is
reflected in the above formula by a decrease in the divider
from 1,5 to 1,2. In view of the longer half-life of factor
IX (about 20 hours), therapy need be given only once or
twice per day. The commercial preparations of factor IX
are less satisfactory than those of factor VIII and apart
from the same danger of hepatitis, thrombotic"" and
anaphylactic reactions"" and disseminated intravascular co·
agulation complications have been reported....·4l Home
therapy may be conducted with these preparations or with
FFP. The danger of thrombosis developing may be due
to the presence of activated factor X in the concentrates.
Such activated preparations should not be used except
in special situations (see below).
INHIBITORS
Inhibitors are antibodies to factor VIII or IX, usually of
the IgG class:"" but occasionally IgM...·" or a combina-
tion of IgG and IgM .....··' They occur in 5 - 21 "{, of the
haemophihc population.""'''' Rarely, inhibitors have also
been described in non-haemophiliacs, especially in women
during the postpartum period, in patients with auto-
immune diseases and in the elderly. They rarely occur
without underlying disease, and have been reported as
reactions to drugs, especially penicillin:' We have not
seen inhibitors to factor IX, but Nilsson and Hedner"
quote an incidence of 10% in Sweden.
Infusions of factor VIII usually produce a marked
anamnestic rise in the antibody level after 3 - 4 days and
it may take 4 - 8 months before it falls to pre-infusion
levels. For practical purposes all patients with inhibitors
are severely affected haemophiliacs and in only a few
cases have inhibitors been reported in mild haemo-
phiha." In view of the antibody nature of the inhibitor,
corticosteroids and immunosuppressive agents have been
used to suppress the antibody level with variable success.
Corticosteroids have not proved to be of much value and
the immunosuppressive agent with the best results is
cyclophosphamide. This agent has been most effective in
inhibitors occurring in the postpartum period or asso-
ciated with underlying diseases. Complete eradication of
the inhibitor has occurred in only 6 patients with haemo-
philia A, who have subsequently received factor VIll
without antibody reappearance.""';;'; In a larger number
of patients the anamnestic response has been blunted or
even prevented,""" but in the majority of cases immuno-
suppressive therapy has been a complete failure.'"'"''''
Patients with non-haemophilic inhibitors have been re-
ported to have spontaneous remissions, especially in post·
partum cases and those associated with auto-immune
diseases. In patients with no underlying disease, inhibitors
respond to therapy less frequently and spontaneous re·
mission is uncommon.6l
Recently, prothrombin complex concentrates have been
used in patients with inhibitors. with good results.
Abildgaard et al..~,63 have recently reported the use of the
factor IX concentrate Konyne to ueat 64 bleeding episodes
in 5 haemophilic patients with factor VIII inhibitors.
Prompt control of bleeding was observed in each instance
with factor IX doses of 15 - 100 Ujkg and no complica-
tions were encountered. Both Auto-factor IX and Proplex
have been reported as being equally effective."' There does
not appear to be a relationship between these concentrates
and inhibitor level, and no increase in dosage is required
for high levels. The exact mechanism of action is not
fully known, but it would appear that a high content of
activated factors IX and X is necessary to bypass the need
for factor VIII in the coagulation process. Thrombotic'
and anaphylactic reactions'" and disseminated intravascular
coagulation have been reported with the use of these
concentrates. especially in the presence of liver disease:·")
Porcine and bovine factor VIII are also available for
the therapy of patients with inhibitors. They are effective
in the short term only, since there is some cross-reactivity,
and antibodies to these animal factor VIII preparations
build up rapidly. Their use may be life-saving.
VON WILLEBRAND'S DISEASE
In 1926 von Willebrand described a family with a bleeding
diathesis in whom the affected members had a prolonged
bleeding time, normal coagulation time and normal platelet
count and morphology. In addition, the disorder is now
known to be associated with low factor VIII levels and a
prolonged and progressive rise of factor VIU after infusion
of plasma or factor VIII. It is inherited as an autosomal
dominant gene with variable penetrance and expression""
and affects females slightly more commonly than males.
More severely affected patients present early in life
with a tendency to prolonged bleeding from superficial
cuts and scratches and with bleeding from nose, mouth
and gums. Haemarthroses occur in up to 50()~ of severely
affected patients. Gastro-intestinal bleeding is not un-
common and difficulty is often encountered in determining
this source.
Patients with mild von Willebrand's disease have only
mild spontaneous bleeding, mainly nose-bleeding, gingival
bleeding, bruises and menorrhagia.
The diagnosis is usually not difficult. There is a low
factor VHI level, prolonged bleeding time, failure of
platelets to aggregate with ristocetin, and a prolonged rise
of factor VIII after infusion not only of normal plasma
and antihaemophilic globulin, but also of haemophilic
plasma. On the other hand. transfusion of von
Willebrand's plasma into haemophiliacs does not raise
their level of factor VIII.
Principles of therapy are the same as in haemophiliac
patients. Less factor VIII is required because of the en-
dogenous manufacture of factor VIn after transfusion.
PSYCHOLOGICAL ASPECTS
The haemophilic child usually grows up in a very pro-
tected environment. He is often cloistered by parents
with guilt feelings, and reacts either by denial of his
illness or by overdependence. Many children and parents
do not wish to discuss the illness and regard it as some-
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thing of a stigma. However. very many families and
patients adjust well to their difficulties, and schooling
takes its normal course, but patients may not participate
in contact sports. In severely affected patients the atlitude
of the school is important and a visit to the teacher by
the family practitioner may assist understanding of the
problems that may arise. Generally, home infusion has
drastically reduced the days lost from school because
of haemorrhages and some patients maintain a supply of
dried factor VIII at school. Patients are soon accepted by
their peers, but may initially have to endure questioning
and even teasing. Subsequent career opportunities are
dependent upon school education. Problems in earning a
livelihood often result from unsatisfactory school educa-
tion.
The South African Haemophilia Foundation aims to
improve understanding of haemophilia among doctors and
laymen, supports research into the condition and assists
haemophiliacs. All patients and their families are urged to
participate actively in the Foundation.
Finally, we feel that no couple of whom the woman is
a potential haemophilia carrier should deny themselves
the right to a family. Even if a child is affected, modern
treatment may prevent crippling deformity. and the
haemophilic patient may have a full and rewarding life.
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